Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.57 |
| ▸ | ALDH3A1 | P30838 | 7/20 | 0.57 |
| ▸ | ALDH2 | P05091 | 4/20 | 0.57 |
| ▸ | CUL4A | Q13619 | 1/20 | 0.57 |
| ▸ | CES1 | P23141 | 1/20 | 0.56 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.45 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 2/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
| ▸ | PARK7 | Q99497 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21001776 | 0.94 | ACHE (0.57) | ACHEALDH1A1ALDH3A1ALDH2CUL4A | |
| SCHEMBL13196466 | 0.85 | CUL4A (0.43) | ACHEALDH1A1ALDH3A1ALDH2CUL4A | |
| SCHEMBL2762340 | 0.78 | POLB (0.60) | ALDH1A1ALDH3A1CHRM5CASP3CASP7 | |
| SCHEMBL4144086 | 0.78 | CUL4A (0.60) | ACHEALDH1A1ALDH3A1ALDH2CUL4A | |
| SCHEMBL30403461 | 0.78 | CUL4A (0.68) | ACHEALDH1A1ALDH3A1ALDH2CUL4A | |
| SCHEMBL22667286 | 0.78 | CUL4A (0.68) | ACHEALDH1A1ALDH3A1ALDH2CUL4A | |
| SCHEMBL22655345 | 0.77 | CA1 (0.40) | ACHEALDH1A1ALDH3A1ALDH2CUL4A | |
| SCHEMBL22655346 | 0.77 | CA1 (0.40) | ACHEALDH1A1ALDH3A1ALDH2CUL4A | |
| SCHEMBL29220077 | 0.76 | ALDH1A1 (0.67) | ACHEALDH1A1ALDH3A1ALDH2CUL4A | |
| SCHEMBL21001752 | 0.75 | ALDH1A1 (0.65) | ACHEALDH1A1ALDH3A1ALDH2CUL4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4648853-A1 | TARGETED DEGRADATION OF VAV1 | Monte Rosa Therapeutics AG (CH) | 2025-11-19 | — | — | EP | disclosed |
| US-20250205219-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS AG (CH) | 2025-06-26 | — | — | US | disclosed |
| US-12257247-B2 | Targeted degradation of VAV1 | MONTE ROSA THERAPEUTICS AG (CH) | 2025-03-25 | — | — | US | disclosed |
| US-20240285604-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS AG (CH) | 2024-08-29 | — | — | US | disclosed |
| WO-2024151547-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024151547-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240285604-A1 | TARGETED DEGRADATION OF VAV1 | VAV1, KRAS, CBL | ACHE 4816/4885ALDH1A1 3624/4885ALDH3A1 3969/4885 |
| US-12257247-B2 | Targeted degradation of VAV1 | VAV1, KRAS, CBL | ACHE 4816/4885ALDH1A1 3624/4885ALDH3A1 3969/4885 |
| US-20250205219-A1 | TARGETED DEGRADATION OF VAV1 | VAV1, KRAS, CBL | ACHE 4816/4885ALDH1A1 3624/4885ALDH3A1 3969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.